Timber pharmaceuticals announces completion of patient enrollment in phase 2b control study evaluating tmb-001 in congenital ichthyosis

- company plans to ask for end-of-phase 2 meeting with fda by end of 2021 -
TMBR Ratings Summary
TMBR Quant Ranking